Affichem appoints SAFC to provide chemical development services

Published: 17-Jan-2007
Research & Development

SAFC Pharma, a business segment of Sigma-Aldrich Fine Chemicals (SAFC) has been appointed by French biotech firm Affichem to provide chemical development services relating to Dendrogenine A, a potential cancer treatment.


SAFC Pharma, a business segment of Sigma-Aldrich Fine Chemicals (SAFC) has been appointed by French biotech firm Affichem to provide chemical development services relating to Dendrogenine A, a potential cancer treatment.

Dendrogenine A, currently in pre-clinical development, is a new first in class molecule dedicated to the treatment of aggressive cancers. This compound contains an original mechanism of action, which makes tumour-producing, tumour-specific antigens and activates the cytotoxic T response against the tumour through the stimulation of the monocyte differentiation into dendritic like cells.

Chemists at the SAFC Manchester facility plan to conduct process r&d on the synthesis of the material to determine a suitable process for producing sufficient quantities of Dendrogenine A for future clinical trials and cGMP commercial production.

  • Companies:
  • Merck Group
See more

You may also like

Research & Development

Amphista Therapeutics reaches research milestone and triggers a milestone payment from Merck

Read more
Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue degraders for oncology and immunology indications

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Servier acquires potential treatment for Fragile X syndrome KER-0193, a novel, orally bioavailable small molecule, was granted orphan drug and rare paediatric drug designation by the US FDA
  3. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  4. Ryvu to support BioNTech’s clinical trials for cancer in Poland Ryvu will leverage its clinical network to streamline access to BioNTech’s investigational immunotherapies for Polish patients
  5. Intranasal GLP-1 medication from Orexo shows positive results in preclinical trial Orexo's AmorphOX technology had positive results when compared against oral and injectable formulations in the study

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Research & Development

Amphista Therapeutics reaches research milestone and triggers a milestone payment from Merck

Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue degraders for oncology and immunology indications
Research & Development

Quibim partners with Merck KGaA to develop imaging-based diagnostics

Quibim and Merck KGaA have partnered to develop diagnostic tools which will fortify the implementation of personalised medicine
Drug Delivery

Curia and MilliporeSigma sign deal for use of cell line for proteins and antibodies

Following this agreement, the CHOZN GS-/- cell line has been integrated into Curia’s cell line development workflow and is immediately available to Curia customers
Regulatory

Merck announces collaboration with Agilent to fill PAT gap for downstream processing

Collaboration will help to enable real-time release and Bioprocessing 4.0
Research & Development

BioMed X Institute and Merck begin second immunology project

Team TDA will join the three ongoing research groups sponsored by Merck, which follow four completed projects
Research & Development

eTheRNA announces mRNA research agreement with Merck

The ongoing pandemic has underlined the capability for mRNA vaccines as a therapeutic modality
Research & Development

BioMed X completes fourth oncology project with Merck

The next project team: “Synthetic Lethality in DNA Repair” (SDR) is led by Dr Özdemirhan Serçin, who was a postdoctoral researcher in the DDC teamv
Subscribe now